We analyzed the relationship between recovery from coronary artery aneurysms (CAAs) and concurrent infections in patients with Kawasaki disease (KD). The estimated median time of aneurysm persistence between patients with and without infections was compared using Kaplan-Meier survival analyses. Risk factors associated with persistent CAAs at 2 years were identified using multivariable analyses. Co-infection was confirmed in 20.5% (106/518) of patients diagnosed with KD. No significant differences regarding treatment or coronary artery outcome were identified between patients with and without infections. The estimated median time of aneurysm persistence was higher in the co-infected group (9 vs. 6 months). A maximum Z-score ≥ 4.00 at 1 month had 78% sensitivity and 83% specificity in predicting CAAs without recovery within 1 year of onset, whereas the predictability was higher within 2 years of onset, with a Z-score ≥ 4.88 (sensitivity, 92%; specificity, 91%). Concomitant infections did not affect the response to treatment or coronary artery outcomes in patients with KD.
McCrindleBWManlhiotC.SARS-CoV-2-related inflammatory multisystem syndrome in children: different or shared etiology and pathophysiology as Kawasaki disease?JAMA. 2020;324(3):246-248. doi:10.1001/jama.2020.10370.
2.
WhittakerEBamfordAKennyJ, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259-269. doi:10.1001/jama.2020.10369.
3.
KatsumataNHaramaDTodaT, et al. Prevention measures for COVID-19 and changes in Kawasaki disease incidence. J Epidemiol. 2021;31(11):573-580. doi:10.2188/jea.JE20210132.
PrincipiNRiganteDEspositoS.The role of infection in Kawasaki syndrome. J Infect. 2013;67(1):1-10. doi:10.1016/j.jinf.2013.04.004.
6.
KimGBParkSKwonBSHanJWParkYWHongYM.Evaluation of the temporal association between Kawasaki disease and viral infections in South Korea. Korean Circ J. 2014;44(4):250-254. doi:10.4070/kcj.2014.44.4.250.
7.
MoritaAImadaYIgarashiHYutsudoT.Serologic evidence that streptococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol Immunol. 1997;41(11):895-900. doi:10.1111/j.1348-0421.1997.tb01947.x.
8.
HallMHoytLFerrieriPSchlievertPMJensonHB.Kawasaki syndrome-like illness associated with infection caused by enterotoxin B-secreting Staphylococcus aureus. Clin Infect Dis. 1999;29(3):586-589. doi:10.1086/598638.
9.
KonishiNBabaKAbeJ, et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr. 1997;86(6):661-664. doi:10.1111/j.1651-2227.1997.tb08952.x.
10.
FerwerdaAMollHAde GrootR.Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr. 2001;160(8):483-491. doi:10.1007/s004310100775.
11.
ChuaPKNerurkarVRYuQWoodwardCLMelishMEYanagiharaR.Lack of association between Kawasaki syndrome and infection with parvovirus B19, human herpesvirus 8, TT virus, GB virus C/hepatitis G virus or Chlamydia pneumoniae. Pediatr Infect Dis J. 2000;19(5):477-479. doi:10.1097/00006454-200005000-00019.
12.
KuijpersTWHerweijerTJSchölvinckLWertheim-Van DillenPMVan De VeerEM.Kawasaki disease associated with measles virus infection in a monozygotic twin. Pediatr Infect Dis J. 2000;19(4):350-353. doi:10.1097/00006454-200004000-00018.
13.
KangJMJungJKimYE, et al. Temporal correlation between Kawasaki disease and infectious diseases in South Korea. JAMA Netw Open. 2022;5(2):e2147363. doi:10.1001/jamanetworkopen.2021.47363.
14.
ChangLYLuCYShaoPL, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014;113(3):148-154. doi:10.1016/j.jfma.2013.12.008.
15.
RifeEGedaliaA.Kawasaki disease: an update. Curr Rheumatol Rep. 2020;22(10):75. doi:10.1007/s11926-020-00941-4.
16.
TurnierJLAndersonMSHeizerHRJonePNGlodéMPDominguezSR.Concurrent respiratory viruses and Kawasaki disease. Pediatrics. 2015;136(3):e609-e614. doi:10.1542/peds.2015-0950.
17.
BenselerSMMcCrindleBWSilvermanEDTyrrellPNWongJYeungRS.Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics. 2005;116(6):e760-e766. doi:10.1542/peds.2005-0559.
18.
DionneALeCKPoupartS, et al. Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection. PLoS One. 2018;13(10):e0206001. doi:10.1371/journal.pone.0206001.
19.
Jordan-VillegasAChangMLRamiloOMejíasA.Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J. 2010;29(8):770-772. doi:10.1097/INF.0b013e3181dba70b.
20.
de FerrantiSDSteinbergerJAmeduriR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation. 2019;139(13):e603-e34. doi:10.1161/CIR.0000000000000618.
21.
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents:summary report. Pediatrics. 2011;128(suppl 5):S213-S256. doi:10.1542/peds.2009-2107C.
22.
GongXTangLWuM, et al. Development of a nomogram prediction model for early identification of persistent coronary artery aneurysms in Kawasaki disease. BMC Pediatr. 2023;23(1):79. doi:10.1186/s12887-023-03876-8.
23.
LiuJSuDYuanP, et al. Prognostic nutritional index value in the prognosis of Kawasaki disease with coronary artery lesions. Front Nutr. 2023;10:1075619. doi:10.3389/fnut.2023.107561.
24.
NewburgerJWTakahashiMGerberMA, et al. Diag-nosis, treatment, and long-term management of Kawa-saki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-2771. doi:10.1161/01.CIR.0000145143.19711.78.
25.
McCrindleBWRowleyAHNewburgerJW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484.
26.
ParkHRHanMYYoonKLChaSHMoonSKJungHW.Mycoplasma infection as a cause of persistent fever after intravenous immunoglobulin treatment of patients with Kawasaki disease: frequency and clinical impact. Infect Chemother. 2017;49(1):38-43. doi:10.3947/ic.2017.49.1.38.
27.
LanYLiSYangD, et al. Clinical characteristics of Kawasaki disease complicated with Mycoplasma pneumoniae pneumonia: a retrospective study. Medicine (Baltimore). 2020;99(19):e19987. doi:10.1097/MD.0000000000019987.
28.
LeeMNChaJHAhnHM, et al. Mycoplasma pneumoniae infection in patients with Kawasaki disease. Korean J Pediatr. 2011;54(3):123-127. doi:10.3345/kjp.2011.54.3.123.
29.
LeeKYRhimJWKangJH.Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a “protein homeostasis system.” Yonsei Med J. 2012;53(2):262-275. doi:10.3349/ymj.2012.53.2.262.
30.
TseSMSilvermanEDMcCrindleBWYeungRS.Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002;140(4):450-455. doi:10.1067/mpd.2002.122469.
31.
WilsonNHeatonPCalderLNicholsonRStablesSGavinR.Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience. J Paediatr Child Health. 2004;40(9-10):524-529. doi:10.1111/j.1440-1754.2004.00456.x.
32.
DionneAIbrahimRGebhardC, et al. Coronary wall structural changes in patients with Kawasaki disease: new insights from optical coherence tomography (OCT). J Am Heart Assoc. 2015;4(5). doi:10.1161/JAHA.115.001939.
33.
MaricLSKnezovicIPapicN, et al. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience. Rheumatol Int. 2015;35(6):1053-1058. doi:10.1007/s00296-014-3186-9.
34.
McCrindleBWHarrisKC.Coronary artery aneurysms after Kawasaki disease: understanding the pathology. Can J Cardiol. 2018;34(9):1094-1097. doi:10.1016/j.cjca.2018.07.412.
35.
Ram KrishnaMSundaramBDhanalakshmiK. Predictors of coronary artery aneurysms in Kawasaki disease. Clin Pediatr (Phila). 2014;53(6):561-565. doi:10.1177/0009922814530802.
36.
GuoCTanCXiaX, et al. Tumour necrosis factor-α and myoglobin associated with the recovery time of coronary artery lesions in Kawasaki disease patients. J Paediatr Child Health. 2020;56(9):1382-1387. doi:10.1111/jpc.14942.
37.
LiTQiMDongG, et al. Clinical value of prognostic nutritional index in prediction of the presence and severity of neonatal sepsis. J Inflamm Res. 2021;14:7181-7190. doi:10.2147/JIR.S343992.
38.
TaiIHWuPLGuoMM, et al. Prognostic nutrition index as a predictor of coronary artery aneurysm in Kawasaki Disease. BMC Pediatr. 2020;20(1):203. doi:10.1186/s12887-020-02111-y.
39.
LiGXuXChenPZengRLiuB.Prognostic value of pretreatment prognostic nutritional index in intravenous immunoglobulin-resistant Kawasaki disease. Heart Vessels. 2021;36(9):1366-1373. doi:10.1007/s00380-021-01819-w.
40.
YalcinkayaRÖzFNDurmuşSY, et al. Is there a role for laboratory parameters in predicting coronary artery involvement in Kawasaki disease. Klin Padiatr. 2022;234(6):382-387. doi:10.1055/a-1816-6754.
41.
LiuXShaoSWangL, et al. Predictive value of the systemic immune-inflammation index for intravenous immunoglobulin resistance and cardiovascular complications in Kawasaki disease. Front Cardiovasc Med. 2021;8:711007. doi:10.3389/fcvm.2021.711007.
42.
AkagiTRoseVBensonLNNewmanAFreedomRM.Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr. 1992;121:689-694. doi:10.1016/s0022-3476(05)81894-3.
43.
BeitzkeAZobelG.Coronary aneurysm in Kawasaki syndrome: incidence and prognosis. Klin Padiatr. 1989;201(1):33-39. doi:10.1055/s-2007-1025272.
44.
FujiwaraTFujiwaraHHamashimaY.Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinicopathologic study of coronary aneurysms. Prog Clin Biol Res. 1987;250:519-520.
45.
TakahashiMMasonWLewisAB.Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation. 1987;75(2):387-394. doi:10.1161/01.cir.75.2.387.
46.
MitaniYTsudaEKatoH, et al. Emergence and characterization of acute coronary syndrome in adults after confirmed or missed history of Kawasaki disease in Japan: a Japanese nationwide survey. Front Pediatr. 2019;7:275. doi:10.3389/fped.2019.00275.
47.
TsudaEKamiyaTOnoYKimuraKKurosakiKEchigoS.Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr Cardiol. 2005;26(1):73-79. doi:10.1007/s00246-004-0698-1.
48.
FriedmanKGGauvreauKHamaoka-OkamotoA, et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population. J Am Heart Assoc. 2016;5(9):e003289. doi:10.1161/JAHA.116.003289.
49.
SonMBFGauvreauKTremouletAH, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 2019;8(11):e011319. doi:10.1161/JAHA.118.011319.
50.
KatoHSugimuraTAkagiT, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379-1385. doi:10.1161/01.cir.94.6.1379A.
51.
LiuJYueQQinSSuDYeBPangY.Risk factors and coronary artery outcomes of coronary artery aneurysms differing in size and emergence time in children with Kawasaki disease. Front Cardiovasc Med. 2022;9:969495. doi:10.3389/fcvm.2022.969495.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
